Medical Oncologist
CION Cancer Clinics
Combined HCC-cholangiocarcinoma: the mixed liver tumour explained | CION Cancer Clinics
Combined HCC-cholangiocarcinoma is a rare cancer that starts in the liver and contains two kinds of cancer cell in one tumour. Part behaves like hepatocellular carcinoma and part like bile duct cancer. This page explains how it is found, why it is often named only after surgery, how it is treated and what to ask your team. At CION Cancer Clinics in Hyderabad, our oncologists explain liver cancer in plain words and plan care around you and your family.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is a combined HCC-cholangiocarcinoma?
- Why is a mixed liver tumour so hard to recognise?
- How do doctors confirm a combined liver cancer?
- How is it treated compared with HCC or bile duct cancer?
- Which medicines are used when surgery is not possible?
- What families often assume, and what is actually true
- What this page cannot tell you
- Common questions about combined HCC-cholangiocarcinoma
The short answer
What is a combined HCC-cholangiocarcinoma?
It is a rare primary liver cancer that contains two kinds of cancer cell in the same tumour. Some cells behave like hepatocellular carcinoma (HCC), the cancer of the main liver cells. Others behave like cholangiocarcinoma, the cancer of the small bile ducts inside the liver.
Doctors also call it a mixed tumour, combined liver cancer or cHCC-CCA. It starts in the liver itself. It is not cancer that spread to the liver from the bowel, breast or another organ. If your report says the liver spots came from somewhere else, this page is not about you, and the page on primary and secondary liver cancer is a better place to start.
Why the label matters
HCC and cholangiocarcinoma are usually treated quite differently. A tumour that carries both raises a real question about which plan fits best. Because it is uncommon, there are few large studies to guide that choice. Your team will usually lean on the part of the tumour that seems to be driving the illness, and on what can safely be done for your liver.
This is a diagnosis made by a pathologist looking at tissue. A scan alone cannot confirm it.How it comes to light
Why is a mixed liver tumour so hard to recognise?
It borrows features from both of its parent cancers. That is exactly what makes it easy to miss before tissue is examined.
The scan can look like either cancer
On a triple-phase CT or MRI, HCC has a typical pattern of how it takes up and loses the contrast dye. A mixed tumour may show that pattern in one part and a bile duct pattern in another. Sometimes it looks like plain HCC throughout.
The blood markers can point both ways
AFP, a protein often raised in HCC, and CA 19-9, a marker often raised in bile duct cancer, may both be high. Either can also be normal. Markers support the picture. They do not settle it.
It often appears in a damaged liver
Like HCC, it is often found in people with hepatitis B, hepatitis C, fatty liver or cirrhosis, meaning a scarred liver. It can also appear in a liver that looked healthy.
Often found
- On a surveillance scan for hepatitis or cirrhosis
- On a scan done for vague pain or weight loss
- Only after an operation, when the removed tumour is examined
The answer sometimes comes after surgery
Many people are first told they have HCC. The mixed nature is found when the pathologist studies the whole tumour after it is removed. That is not a mistake by anyone. A needle sample sees only a small part.
Not sure whether this applies to you?
Ask an oncologistReaching a diagnosis
How do doctors confirm a combined liver cancer?
A good-quality liver scan
A triple-phase CT or liver MRI shows the size, number and position of the tumours and the blood vessels around them. CION arranges these through accredited diagnostic partners.
A biopsy when the picture is unusual
Typical HCC can often be diagnosed on a scan alone. When the scan or markers do not fit, a needle sample of the tumour is taken through a partner hospital. Read more on when a liver biopsy is necessary.
Special stains in the laboratory
The pathologist uses stains that mark liver-type cells and bile duct-type cells. Seeing both, in one tumour, is what makes the diagnosis.
A second look at the slides
Because the tumour is rare, a second pathology opinion is reasonable and common. See second-opinion pathology for a rare liver tumour.
The tumour board decides together
The scans, the pathology, your liver function and your general fitness go to a multidisciplinary tumour board before any plan is offered.
Side by side
How is it treated compared with HCC or bile duct cancer?
Situation
What the team usually considers
Tumour can be removed and the liver is strong enough
Surgery to remove it, planned by surgical oncologists, with curative intent
Small tumour, surgery not safe
Ablation or other local treatment may be discussed, through partner hospitals
Transplant
Not a standard route for a known mixed tumour; decided case by case at a licensed transplant centre
Tumour cannot be removed or has spread
Systemic treatment, often borrowed from bile duct cancer or from HCC care
Tumour tissue available
Molecular testing, to look for a change that a targeted medicine might act on
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Medicines
Which medicines are used when surgery is not possible?
There is no treatment designed only for this tumour. Oncologists usually borrow from one of the two parent cancers. Some teams start with the combination used for bile duct cancer, such as gemcitabine with cisplatin, sometimes with an immunotherapy medicine like durvalumab. Others use the medicines used in HCC, such as atezolizumab with bevacizumab, or tablets like lenvatinib or sorafenib.
The choice depends on which part of the tumour seems to lead, how well your liver works, your blood counts and your other illnesses. The evidence comparing these choices in mixed tumours is thin, and an honest oncologist will tell you so. How each medicine works and its side effects are covered on chemotherapy for gallbladder and bile duct cancer and immunotherapy for HCC.
Why the tumour's DNA should be tested
Bile duct-type cancers sometimes carry changes, such as an FGFR2 fusion or an IDH1 change, that a targeted medicine can act on. Testing the tumour tissue is worth asking about. It may or may not find such a change. If it does, some of these medicines are available in India only through import or trials, and your oncologist will explain what is realistic.
Commonly believed
What families often assume, and what is actually true
"The first doctor got it wrong because it was called HCC."
A needle sample sees only a small piece. The mixed nature often shows only when the whole tumour is examined. A change of label after surgery is how this disease is commonly found.
"Two cancers in one tumour means two cancers in the body."
It is one tumour with two kinds of cell. It is staged and treated as one cancer.
"A rare tumour means nothing can be done."
Surgery is possible for some people, and medicines used for both parent cancers are available. Rarity means less evidence, not no options.
"The biopsy will make it spread."
The risk of a biopsy seeding cancer along the needle track is low, and it is weighed carefully. Your team takes a sample only when the result will change the plan.
Being straight with you
What this page cannot tell you
It cannot tell you whether your tumour is mixed. Only a pathologist looking at your tissue, often with special stains, can say that. It also cannot tell you which treatment suits you, or what to expect for yourself. Those answers depend on your scans, your liver function and your fitness.
Who this page does not apply to
It does not apply if your report says HCC alone, or bile duct cancer alone, or cancer that has spread to the liver from another organ. It is not about gallbladder cancer, which has its own pages, or about liver tumours in children.
Who can answer your questions
Your medical oncologist, your liver surgeon and the pathologist who read your slides. At CION, the tumour board reviews the whole picture, and a second opinion on the plan or the pathology can be arranged.
Bring every scan, the biopsy or operation report and your latest blood tests to the first visit.Questions we are asked
Common questions about combined HCC-cholangiocarcinoma
Is combined HCC-cholangiocarcinoma a type of liver cancer?
Yes. It is a primary liver cancer, meaning it started in the liver. It contains cells that look like HCC and cells that look like bile duct cancer, in the same tumour. It is much less common than either of those two cancers on its own.
Is it more serious than ordinary HCC?
It is often described as behaving more like bile duct cancer than HCC. Even so, every tumour and every liver is different. Your own outlook depends on size, spread, liver function and fitness. Ask your oncologist to explain your situation rather than relying on general statements.
Can it be removed with surgery?
Sometimes. If the tumour is confined to the liver and enough healthy liver will remain, surgery is the main option with curative intent. CION's surgical oncologists assess this, and your team will tell you where the operation takes place.
Can I have a liver transplant for this tumour?
A transplant is not a standard route when a mixed tumour is known before surgery. Sometimes the diagnosis is made only after a transplant done for presumed HCC. Licensed transplant centres decide eligibility. Rules and practice change, so check with the transplant team directly.
Why did my report change after the operation?
The pathologist studied the whole tumour, not just a needle sample or a scan. Finding both kinds of cell changes the name. It may also change what follow-up and further treatment your team recommends, so ask what the new label means for your plan.
Should the tumour be tested for gene changes?
It is worth asking. The bile duct-type part can carry changes that a targeted medicine acts on. Testing may find nothing useful, and no option is promised. Your oncologist will tell you whether there is enough tissue and what a result could change.
Is it hereditary?
It is not usually thought of as inherited. It tends to arise in a liver damaged by hepatitis B, hepatitis C, fatty liver or cirrhosis. If hepatitis B runs in your family, testing and vaccinating relatives is sensible, and nobody is to blame for it.
How does CION help with this diagnosis?
CION offers consultations and second opinions, reviews your case at a tumour board, and gives chemotherapy, immunotherapy and targeted therapy. Scans, biopsy and surgery are coordinated through accredited partner hospitals. One helpline serves every CION centre.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- National Cancer Institute — What Is Bile Duct Cancer (Cholangiocarcinoma)?
- American Cancer Society — Bile Duct Cancer Targeted Therapy
- MedlinePlus — Liver cancer - hepatocellular carcinoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
How cholangiocarcinoma differs from HCCThe two parent cancers, side by sideWhy every biliary cancer should be molecularly testedWhat a DNA test on the tumour can changeSecond-opinion pathology for a rare liver tumourWhen and how to get the slides looked at againTypes of primary liver cancerWhere this tumour sits among the others
Talk to us
Has your report been changed to a mixed liver tumour?
Send us your scans and pathology report and the tumour board will review what the new label means for your plan. We can also arrange a second look at the slides. One helpline serves every CION centre.